Peptide Library

Human study PLS-00197

β-Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up.

Prospective cohort · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • β-Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up.primary · Respiratory research · 2011-02-11 · PMID 21314931 · DOI

Design and participants

Design
Prospective cohort
Population
46 systemic sclerosis (scleroderma) patients with lung involvement and 15 controls who underwent bronchoalveolar lavage; patients were followed for one year.
Conditions
Systemic sclerosis, Interstitial lung disease
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors report beta-thymosins in bronchoalveolar lavage fluid for the first time and suggest a role in scleroderma lung disease. Higher endogenous thymosin beta-4 appeared protective against lung damage, while its oxidised form reflected alveolar inflammation.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin beta-4 was only measured as an endogenous biomarker in lavage fluid and was never given as a treatment.
    • abstract only: Only the abstract is available in the record, so methods and full results cannot be appraised.
    • confounding: The associations between thymosin levels and lung disease progression are observational and may be confounded.
    • inappropriate population: Participants were not given thymosin β4; the study measured endogenous levels as a biomarker, so it is not an intervention study.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 21314931, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 21314931, title (title) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 21314931, abstract (Background, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 21314931, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 21314931, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).